Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Sep 30;17(9):e0275393. doi: 10.1371/journal.pone.0275393

Body mass index and stroke risk among patients with diabetes mellitus in Korea

Do Kyeong Song 1, Young Sun Hong 1, Yeon-Ah Sung 1, Hyejin Lee 1,*
Editor: Tariq Jamal Siddiqi2
PMCID: PMC9524704  PMID: 36178901

Abstract

Background

Obesity and diabetes mellitus (DM) are both associated with cardiovascular disease. This study aimed to evaluate the association between body mass index (BMI) and stroke risk among patients with DM in Korea since relatively few studies have analyzed this area in detail.

Methods

We analyzed a total of 56,051 DM patients aged >30 years from the Korean National Health Insurance Service Cohort who had undergone at least one national health examination between 2002 and 2012. BMI scores were divided into six categories, while hazard ratios for stroke were calculated using Cox proportional hazard models.

Results

Overall stroke risk was positively associated with BMI for both men and women. For ischemic stroke, the risk was positively associated with BMI in women. However, for me, only patients with the highest BMI were at increased risk compared with patients with a BMI of 20–22.4 kg/m2. For hemorrhagic stroke, the risk was significantly associated with BMI with a U-shaped association in men. In women, only patients with the lowest BMI had an increased risk of hemorrhagic stroke compared with patients that have a BMI of 20–22.4 kg/m2.

Conclusion

BMI was positively associated with the overall risk of stroke among DM patients in Korea. The risk of ischemic stroke was higher in obese patients compared to overweight or normal-weight patients. However, the risk of hemorrhagic stroke was higher in slimmer patients compared with overweight or obese patients.

Introduction

Obesity and diabetes mellitus (DM) are both associated with an increased risk of cardiovascular disease, including ischemic heart disease and stroke, which are the leading causes of death [1, 2]. It is also well known that DM is an independent risk factor for cardiovascular disease [3]. People who are overweight or obese are at increased risk of DM. In Korea, the diabetes fact sheet (2020) shows that approximately half of DM patients were considered obese [4]. The risk for cardiovascular events shows a linear association with body mass index (BMI) among Korean adults aged >30 years [5]. Pooled data from 97 prospective cohort studies (after excluding subjects who were younger than 18 years, had a BMI lower than 20 kg/m2, or had a history of cardiovascular disease) showed that being overweight or obese was associated with an increased risk of stroke [6].

However, several studies have suggested the concept of the “obesity paradox,” whereby patients with known coronary artery disease, or those who are overweight or obese, actually had a lower risk of mortality compared to those with BMI within the normal range [7], subsequently among in subjects with DM [8, 9]. Furthermore, there are some controversial results regarding the association between BMI and the risk of cardiovascular events in patients with DM. A Swedish study of 13,087 patients aged 30–74 years with type 2 DM showed that being overweight or obese increased the risk of developing cardiovascular disease, including coronary heart disease or stroke [10]. By contrast, there was an inverse association between BMI and the risk of stroke among patients with type 2 DM who were aged 30–94 years in the USA [11, 12]. In a retrospective Korean observational study from 2009 to 2017, which included 249,903 type 2 DM patients who were aged ≥65 years and with no preexisting cardiovascular diseases, the risk of stroke showed an L-shaped association with BMI [13]. In a prospective Korean cohort study, which included 1,338 type 2 DM patients who had suffered from an acute ischemic stroke, the risk of fatal or non-fatal stroke showed an inverse pattern with BMI score after excluding subjects with active cancer or who had died within one month of suffering a stroke [14].

A stroke is a cardiovascular disease that is a great socioeconomic burden. According to statistics from 2018, mortality can be as high as 30 deaths per 100,000 individuals in Korea. The increasing prevalence of obesity was suggested to be one of the reasons why the incidence of strokes among young and middle-aged adults is increasing [15]. However, there have been few studies regarding the association between BMI and stroke risk in DM patients in Korea, including young and middle-aged adults. Therefore, we aimed to evaluate the association between BMI and stroke risk among Korean patients with DM who were aged >30 years and without preexisting cardiovascular diseases using Korean National Health Insurance data.

Materials and methods

Data source

We analyzed the cohort database from 2002–2012 obtained from the Korean National Health Insurance Service (NHIS). The Korean NHIS program is a universal health insurance program, which most of the Korean population is enrolled in. Therefore, the cohort can be used as a representation of the general population in Korea, and has been described in detail elsewhere [5]. The participants completed a self-administered questionnaire including information on demographic, medical, and behavioral characteristics.

Informed consent was unnecessary because the data were not collected for the study and the patient records were anonymized before being released by the NHIS. Nevertheless, the study was approved by the Institutional Review Board of Ewha Medical Center, and all methods were performed per the relevant guidelines and regulations [16].

Study population and outcome variables

Patients with DM aged >30 years who had undergone at least one national health examination between 2002 to 2012 were enrolled in our study. The patient data were obtained from the Korean NHIS cohort. Subjects who had a medical history of stroke, ischemic heart disease, cancer, or chronic obstructive pulmonary disease were excluded based on the self-reported questionnaire or the medical claims data. Subjects who had missing data, which included height, weight, and fasting glucose levels, were excluded (Fig 1).

Fig 1. Flow chart of participant selection.

Fig 1

We calculated BMI as body weight in kilograms divided by height in meters squared (m2). We divided BMI into six categories: <20, 20–22.4, 22.5–24.9, 25–27.4, 27.5–29.9, and ≥30 kg/m2. DM was identified based on the questionnaire responses, the medical claims data (ICD code I10-I15 or E10-E14), and the health examination measurements (fasting glucose ≥126 mg/dl). Health behaviors including smoking, alcohol consumption, physical activity, and income were evaluated based on the questionnaire as described in detail elsewhere [5]. The outcome of interest was the time-to-stroke incidence. We defined stroke incidence as the first diagnosis of stroke. Stroke was identified as either ischemic stroke (ICD code I63) or hemorrhagic stroke (ICD codes I60-I62).

Statistical analyses

Data are shown as both the frequency and proportion for categorical variables. Hazard ratios (HR) for stroke, both ischemic and hemorrhagic, were calculated using the Cox proportional hazards model according to the various BMI. For reference, we used the 20–22.4 kg/m2 BMI group for the incidence analysis. All HRs were adjusted for age, smoking, alcohol consumption status, levels of physical activity, income, and family history of cardiovascular diseases. In addition, we conducted a sensitivity analysis after excluding subjects who were diagnosed with stroke <3 years after the baseline measurements to avoid the reverse causality between BMI and stroke development.

We conducted analyses separately by gender. P values <0.05 were considered statistically significant. All statistical analyses were performed using SAS (version 9.4, SAS Institute, Cary, NC) or STATA (version 10.0, StataCorp, College Station, Texas).

Results

The baseline characteristics of the subjects are shown in Table 1. Altogether, 415,796 subjects (218,388 men and 197,408 women) who were aged >30 years and without a previous medical history of stroke, ischemic heart disease, cancer, or chronic obstructive pulmonary disease were enrolled in the initial analysis. The median follow-up duration was 7.0 years. Within the cohort, 12% of the men and 17% of the women were aged 60 years or older. Subjects with a BMI of <20 kg/m2 comprised 8% of men and 15% of women, while 32.6% of men and 91.4% of women had never smoked. Only 6.4% of men and 7.1% of women had a family history of cardiovascular disease. After exclusions, 56,051 patients with DM (29,207 men and 26,844 women) were included in the final analysis.

Table 1. Baseline characteristics of the subjects.

Men (n = 218,388) Women (n = 197,408)
Age (years)
    20–39, n (%) 92,645 (42.4) 45,232 (22.9)
    40–49, n (%) 62,200 (28.5) 78,318 (39.7)
    50–59, n (%) 36,732 (16.8) 40,564 (20.5)
    60–69, n (%) 20,026 (9.2) 22,917 (11.6)
    >70, n (%) 6,785 (3.1) 10,377 (5.3)
Body mass index (kg/m2)
    <20, n (%) 17,725 (8.1) 30,184 (15.3)
    20–22.4, n (%) 49,352 (22.6) 58,661 (29.7)
    22.5–24.9, n (%) 71,313 (32.7) 56,999 (28.9)
    25–27.4, n (%) 53,063 (24.3) 31,946 (16.2)
    27.5–29.9, n (%) 19,371 (8.9) 13,210 (6.7)
    ≥30, n (%) 7,564 (3.4) 6,408 (3.2)
Smoking status
    Current smoker, n (%) 104,955 (48.1) 7,575 (3.8)
    Ex-smoker, n (%) 21,047 (9.6) 2,176 (1.1)
    Never smoker, n (%) 71,278 (32.6) 180,390 (91.4)
Family history of CVD, n (%) 13,989 (6.4) 14,003 (7.1)
Hypertension, n (%) 68,111 (31.5) 51,188 (25.9)
Diabetes mellitus, n (%) 29,207 (13.4) 26,844 (13.6)

CVD: cardiovascular disease.

Subjects with a BMI score of <20, 20–22.4, 22.5–24.9, 25–27.4, 27.5–29.9, and ≥30 kg/m2 comprised 6.6%, 18.7% (reference), 31.4%, 26.7%, 11.4%, and 5.2% of men with DM, respectively, and 9.0%, 21.2% (reference), 30.0%, 22.2%, 11.1%, and 6.5% of women with DM, respectively. During the study period, 6.30% (n = 1,840) of men with DM and 6.79% (n = 1,822) of women with DM had suffered an ischemic stroke. Additionally, 1.02% (n = 297) of men with DM and 1.06% (n = 285) of women with DM suffered a hemorrhagic stroke. In both men and women, the overall risk of suffering a stroke, either ischemic or hemorrhagic, was positively associated with BMI and was lowest in patients with a BMI of <20 kg/m2 (HR: men 0.97, women 0.94, p value: men 0.735, women 0.399) (Tables 2 and 3). This linear association between BMI and overall risk of stroke was confirmed in a further sensitivity analysis, which excluded patients who were diagnosed with stroke <3 years after the baseline measurements (Tables 4 and 5).

Table 2. Hazard ratios for stroke risk by different categories of body mass index among men with diabetes mellitus.

Body mass index (kg/m2)
<20 (n = 1,929) 20–22.4 (n = 5,451) 22.5–24.9 (n = 9,176) 25–27.4 (n = 7,813) 27.5–29.9 (n = 3,329) ≥30 (n = 1,509)
HR of stroke incidence (95% CI) 0.97 (0.84–1.13) 1 1.04 (0.94–1.15) 1.14* (1.03–1.26) 1.06 (0.92–1.21) 1.23* (1.01–1.50)
P value 0.735 0.055 0.415 0.014 0.438 0.038
HR of ischemic stroke incidence (95% CI) 0.92 (0.75–1.12) 1 0.97 (0.85–1.10) 1.09 (0.95–1.25) 1.08 (0.90–1.29) 1.38* (1.07–1.78)
P value 0.405 0.040 0.645 0.215 0.390 0.015
HR of hemorrhagic stroke incidence (95% CI) 1.00 (0.64–1.55) 1 0.74 (0.55–1.02) 0.70* (0.50–0.98) 0.89 (0.58–1.36) 0.99 (0.54–1.84)
P value 0.992 0.235 0.064 0.036 0.585 0.978

HRs were adjusted for gender, health behaviors (smoking, alcohol consumption, physical activity), income, and family history of cardiovascular disease.

* P <0.05. HR: hazard ratio; CI: confidence interval.

Table 3. Hazard ratios for stroke risk by different categories of body mass index among women with diabetes mellitus.

Body mass index (kg/m2)
<20 (n = 2,421) 20–22.4 (n = 5,704) 22.5–24.9 (n = 8,042) 25–27.4 (n = 5,976) 27.5–29.9 (n = 2,969) ≥30 (n = 1,732)
HR of stroke incidence (95% CI) 0.94 (0.80–1.09) 1 1.07 (0.97–1.18) 1.11 (1.00–1.23) 1.17* (1.04–1.32) 1.23* (1.06–1.43)
P value 0.399 0.007 0.183 0.050 0.009 0.006
HR of ischemic stroke incidence (95% CI) 0.88 (0.70–1.10) 1 1.12 (0.98–1.29) 1.18* (1.02–1.37) 1.29* (1.09–1.52) 1.47* (1.20–1.79)
P value 0.274 <0.001 0.105 0.024 0.003 <0.001
HR of hemorrhagic stroke incidence (95% CI) 1.90* (1.22–2.95) 1 1.15 (0.81–1.63) 0.84 (0.57–1.24) 1.30 (0.85–1.97) 1.02 (0.58–1.80)
P value 0.004 0.009 0.427 0.373 0.224 0.941

HRs were adjusted for gender, health behaviors (smoking, alcohol consumption, physical activity), income, and family history of cardiovascular disease.

* P <0.05. HR: hazard ratio; CI: confidence interval.

Table 4. Hazard ratios for stroke risk by different categories of body mass index among men with diabetes mellitus after excluding patients who were diagnosed with a stroke less than three years after the baseline measurements.

Body mass index (kg/m2)
<20 20–22.4 22.5–24.9 25–27.4 27.5–29.9 ≥30
HR of stroke incidence 0.97 1 1.08 1.15* 1.06 1.29*
P value 0.764 0.127 0.248 0.034 0.515 0.038
HR of ischemic stroke incidence 0.83 1 0.99 1.10 1.06 1.35
P value 0.166 0.146 0.922 0.296 0.605 0.075
HR of hemorrhagic stroke incidence 1.10 1 0.81 0.62* 1.16 1.06
P value 0.733 0.131 0.301 0.033 0.553 0.875

HRs were adjusted for gender, health behaviors (smoking, alcohol consumption, physical activity), income, and family history of cardiovascular disease.

* P < 0.05. HR: hazard ratio.

Table 5. Hazard ratios for stroke risk by different categories of body mass index among women with diabetes mellitus after excluding patients who were diagnosed with a stroke less than three years after the baseline measurements.

Body mass index (kg/m2)
<20 20–22.4 22.5–24.9 25–27.4 27.5–29.9 ≥30
HR of stroke incidence 0.99 1 1.07 1.04 1.06 1.21*
P value 0.930 0.439 0.301 0.572 0.452 0.044
HR of ischemic stroke incidence 0.94 1 1.14 1.18 1.27* 1.52*
P value 0.648 0.015 0.156 0.089 0.032 0.002
HR of hemorrhagic stroke incidence 1.65 1 1.24 0.99 1.60 1.01
P value 0.117 0.307 0.368 0.971 0.093 0.974

HRs were adjusted for gender, health behaviors (smoking, alcohol consumption, physical activity), income, and family history of cardiovascular disease.

* P < 0.05. HR: hazard ratio.

For ischemic stroke, the risk was positively associated with BMI in women with DM. Similar results were obtained in a further sensitivity analysis, which excluded patients diagnosed with stroke <3 years after the baseline measurements (Tables 3 and 5). However, only men with DM and the highest BMI (HR 1.38, p value 0.015) were at increased risk of ischemic stroke compared to patients with a BMI of 20–22.4 kg/m2. There was no statistical significance in the sensitivity analysis (Tables 2 and 4).

For hemorrhagic stroke, the risk was significantly associated with BMI, with a U-shaped association in men with DM, where patients with a BMI of 25–27.4 kg/m2 (HR 0.70, p value 0.036) showed the lowest level of risk. Similar results were obtained in a further sensitivity analysis, which excluded patients diagnosed with stroke <3 years after the baseline measurements (Tables 2 and 4). In women with DM, only patients with the lowest BMI levels (HR 1.90, p value 0.004) were at increased risk for hemorrhagic stroke compared with patients with a BMI of 20–22.4 kg/m2. However, there were no statistically significant differences in the sensitivity analysis (Tables 3 and 5).

Discussion

Our study analyzed patients with DM who were aged >30 years using the Korean NHIS cohort and found that BMI was positively associated with the overall risk of a stroke. The risk for ischemic stroke was higher in obese patients compared with those who were either overweight or normal weight. However, the risk of hemorrhagic stroke was higher in patients of normal weight than in overweight or obese patients.

Contrary to the results of a previous study, which showed an L-shaped association between BMI and the risk of stroke among Korean type 2 DM patients aged ≥65 years [13], our study showed that there was a linear relationship between BMI and overall stroke risk among DM patients aged >30 years. In line with the present results, an observational study including 13,087 type 2 DM patients aged 30–74 with no history of cardiovascular disease and with no BMI scores <18 kg/m2 in the Swedish National Diabetes Register showed an increased risk of stroke with an increase in BMI after adjustment for age, sex, DM, type of hypoglycemic treatment, and smoking habits [10]. In a prospective cohort study in England, which comprised 10,568 participants with type 2 DM and no known cardiovascular disease at baseline, overweight or obese patients had a higher rate of cardiovascular events than those of normal weight [17]. In a prospective study of 3,708 Finnish type 2 DM patients aged 25–74, higher BMI scores were associated with increased total and cardiovascular mortality [18]. Data from two prospective cohort studies in the USA, which comprised participants with incidental DM who were free of cardiovascular disease or cancer before a DM diagnosis and with BMI scores >18.5 kg/m2 showed that there was a linear relationship between BMI and cardiovascular mortality [19].

However, studies have shown that results showing an association between BMI and the risk of stroke among DM patients with DM are not consistent. Contrary to the results of our study, many studies have shown results consistent with the concept of the “obesity paradox.” In a large retrospective study of 67,086 patients with type 2 DM between the ages of 30 and 94 (40,431 White Americans and 27,113 African Americans), there was a graded inverse association of BMI with the risk of total stroke after excluding subjects with BMI scores <18.5 kg/m2 and adjusting for age, sex, and race [11].

Another retrospective observational study in Louisiana comprising 29,554 patients (aged 30–94, 17,143 African Americans and 12,410 White Americans) who had newly diagnosed type 2 DM showed an inverse association between BMI and overall stroke risk after excluding subjects with a history of stroke and coronary heart disease at the diagnosis and adjusting for age, BMI, race, smoking, income, and insurance type [12]. A study of 25,130 Chinese patients with newly diagnosed type 2 DM, who had no history of myocardial infarction, heart failure, or stroke at baseline and had BMI scores >18.5 kg/m2 showed that subjects with a normal-range BMI had a greater risk of ischemic stroke compared with subjects who were overweight or obese [20]. The rate of cardiovascular mortality was higher in normal-weight participants than in overweight or obese participants from a pooled analysis of five longitudinal cohort studies of 2,625 adults with newly diagnosed DM after excluding subjects with BMI <18.5 kg/m2. However, the association was not statistically significant [8]. In a meta-analysis of two cohort studies of 92,841 participants with type 2 DM, the risk of cardiovascular mortality exhibited a gradual non-linear increase for subjects with BMI >30 kg/m2 and a non-linear decrease for subjects with BMI scores of 22–29 kg/m2 [21]. In a Ukrainian study comprising 30,534 men and 58,909 women with type 2 DM, there was a U-shaped association between BMI and cardiovascular mortality after adjusting for age, smoking status, and alcohol consumption [22]. Levels of physical activity and family history of cardiovascular disease, which could influence the incidence of stroke were not adjusted in the aforementioned studies, and none of the participants were Korean [11, 12, 20, 22]. Subjects who had a medical history of illnesses that could cause low body weight—such as stroke, ischemic heart disease, cancer, or chronic obstructive pulmonary disease—were excluded from our study. However, subjects with chronic diseases such as cancer or chronic obstructive pulmonary disease were not excluded from the previous studies [11, 12, 20, 22]. Differences in study design, sample size, follow-up duration, DM duration, age distribution, smoking history, and inclusion or exclusion criteria may contribute to the differences in the results according to the study.

When stroke subtypes were analyzed separately by gender, we observed subtle differences between men and women. It is well known that although the age-specific rate of stroke incidence is higher in men, women have more stroke events due to their longer life expectancy and the higher incidence of stroke events with age. Scant evidence exists of differences in stroke subtypes between the sexes [23]. Although not completely consistent with our findings, one Japanese study did show differences in the association between BMI and the incidence of stroke depending on sex. Low BMI was a risk factor for total stroke and ischemic stroke in men, while high BMI was a risk factor for total stroke in women among a cohort of 12,490 patients aged 40–69 years after excluding subjects with a history of stroke, myocardial infarction, angina pectoris or cancer [24]. A possible reason for the differences in sex is the difference in sex hormones, the use of oral contraceptives that are known to be associated with increased risk of ischemic stroke, and pregnancy (which increases the risk of thrombosis) [23]. Further studies are required regarding pregnancy, menopause, and the use of oral contraceptives in women with DM.

Ischemic stroke is known to be the most common subtype of stroke in the Korean population, followed by intracerebral hemorrhage and subarachnoid hemorrhage [15]. Similar to the results among the general populace, the number of DM patients with hemorrhagic stroke in Korea was much lower than the number of DM patients with ischemic stroke in our study. However, the association between BMI and the risk of stroke among subjects with DM differed between stroke subtypes. The risk of ischemic stroke was higher in obese patients compared with overweight or normal-weight patients, while the risk for hemorrhagic stroke was higher in normal-weight patients compared with overweight or obese patients. The inconsistency in these results may be caused by the low incidence of hemorrhagic strokes in DM patients. In addition, the different mechanisms of ischemic and hemorrhagic stroke may affect the results regarding the association of BMI and stroke risk in patients with DM. Asian patients are known to be more at risk of DM even if they are of normal weight [25]. It is possible that the genetic profiles of people prone to normal-weight DM might be associated with the different effects of BMI on the incidence of stroke subtypes in subjects with DM [26].

In addition, because BMI cannot depict body composition or body fat distribution, any assessment of obesity based on BMI might be incorrect. Age-related loss of muscle mass could also result in underweight subjects with excess fatty tissue. Further studies are necessary to measure body composition or various parameters representing visceral obesity, such as waist circumference or waist/hip ratio, which are known to be important for metabolic conditions to evaluate the association between obesity and stroke risk in patients with DM.

To the best of our knowledge, the present work is the first large study to evaluate the associations between BMI and the risk of stroke in Korean DM patients with no previous cardiovascular disease. Our sample was sufficiently large because we used NHIS data representing the general Korean population. To reduce the selection bias related to very slim patients with chronic illnesses, we excluded subjects with a history of stroke, ischemic heart disease, cancer, or chronic obstructive pulmonary disease. In addition, we adjusted for age, smoking, alcohol consumption status, levels of physical activity, income, and family history of cardiovascular diseases that can affect the risk of stroke. Because we included subjects from various age groups, the results of our study can be generalized across the country.

There are several limitations to our study. Because we used questionnaire responses, disease codes, or fasting glucose levels to identify patients with DM, we cannot differentiate between type 1 and type 2 DM. Because we did not measure BMI during the follow-up period, we cannot confirm the results according to the change in BMI over time. Additionally, although we adjusted for various confounding factors, residual confounding factors affecting the development of strokes such as dietary factors, hypertension, hypercholesterolemia, or atrial fibrillation might exist. Also, we did not use various parameters representing obesity, as mentioned above. Finally, we cannot verify the mechanism of the association between BMI and the risk of stroke in patients with DM because the study was retrospective.

In conclusion, obesity is positively associated with overall stroke risk, particularly ischemic stroke, among DM patients in Korea. Therefore, active intervention to maintain appropriate body weight is necessary to reduce the risk of stroke among patients with DM. Randomized clinical trials will be necessary to evaluate the risk of stroke depending on changes in body weight or weight-loss therapies. More prospective studies are also needed to clarify the mechanism of the association between BMI and the risk of stroke in patients with DM.

Data Availability

All relevant data are within the manuscript.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448–457. doi: 10.1056/NEJMra1201534 [DOI] [PubMed] [Google Scholar]
  • 2.Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PloS One. 2013;8(7):e65174. doi: 10.1371/journal.pone.0065174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13 000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164(13):1422–1426. doi: 10.1001/archinte.164.13.1422 [DOI] [PubMed] [Google Scholar]
  • 4.Jung C-H, Son JW, Kang S, Kim WJ, Kim H-S, Kim HS, et al. Diabetes Fact Sheets in Korea, 2020: An Appraisal of Current Status. Diabetes Metab J. 2021;45(1):1–10. doi: 10.4093/dmj.2020.0254 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kong KA, Park J, Hong S-h, Hong YS, Sung Y-A, Lee H. Associations between body mass index and mortality or cardiovascular events in a general Korean population. PloS One. 2017;12(9):e0185024. doi: 10.1371/journal.pone.0185024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1· 8 million participants. Lancet. 2013;383 (9921):970–983. doi: 10.1016/S0140-6736(13)61836-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol. 2002;39(4):578–584. doi: 10.1016/s0735-1097(01)01802-2 [DOI] [PubMed] [Google Scholar]
  • 8.Carnethon MR, De Chavez PJD, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308(6):581–590. doi: 10.1001/jama.2012.9282 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kokkinos P, Myers J, Faselis C, Doumas M, Kheirbek R, Nylen E. BMI–mortality paradox and fitness in African American and Caucasian men with type 2 diabetes. Diabetes Care. 2012;35(5):1021–1027. doi: 10.2337/dc11-2407 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Eeg-Olofsson K, Cederholm J, Nilsson P, Zethelius B, Nunez L, Gudbjörnsdóttir S, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65–73. doi: 10.1007/s00125-008-1190-x [DOI] [PubMed] [Google Scholar]
  • 11.Shen Y, Shi L, Nauman E, Katzmarzyk PT, Price-Haywood EG, Bazzano AN, et al. Association between body mass index and stroke risk among patients with type 2 diabetes. J Clin Endocrinol Metab. 2020;105(1):96–105. doi: 10.1210/clinem/dgz032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Li W, Katzmarzyk PT, Horswell R, Zhang Y, Zhao W, Wang Y, et al. Body mass index and stroke risk among patients with type 2 diabetes mellitus. Stroke. 2015;46(1):164–169. doi: 10.1161/STROKEAHA.114.006718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hong S, Park JH, Han K, Lee CB, Kim DS, Yu SH. Association Between Obesity and Cardiovascular Disease in Elderly Patients With Diabetes: A Retrospective Cohort Study. J Clin Endocrinol Metab. 2022;107(2):e515–e527. doi: 10.1210/clinem/dgab714 [DOI] [PubMed] [Google Scholar]
  • 14.Park H, Lee HW, Yoo J, Lee HS, Nam HS, Kim YD, et al. Body mass index and prognosis in ischemic stroke patients with type 2 diabetes mellitus. Front Neurol. 2019;10:563. doi: 10.3389/fneur.2019.00563 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kim JY, Kang K, Kang J, Koo J, Kim D-H, Kim BJ, et al. Executive summary of stroke statistics in Korea 2018: a report from the epidemiology research council of the Korean Stroke Society. J Stroke. 2019;21(1): 42–59. doi: 10.5853/jos.2018.03125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. [DOI] [PubMed] [Google Scholar]
  • 17.Costanzo P, Cleland JG, Pellicori P, Clark AL, Hepburn D, Kilpatrick ES, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Intern Med. 2015;162(9):610–618. doi: 10.7326/M14-1551 [DOI] [PubMed] [Google Scholar]
  • 18.Hu G, Jousilahti P, Barengo NC, Qiao Q, Lakka TA, Tuomilehto J. Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. Diabetes Care. 2005;28(4):799–805. doi: 10.2337/diacare.28.4.799 [DOI] [PubMed] [Google Scholar]
  • 19.Tobias DK, Pan A, Jackson CL, O’Reilly EJ, Ding EL, Willett WC, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370(3):233–244. doi: 10.1056/NEJMoa1304501 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Duan D, Li H, Xu J, Wong L, Xu G, Kong F, et al. Does body mass index and height influence the incident risk of ischemic stroke in newly diagnosed Type 2 diabetes subjects? J Diabetes Res. 2019;2019:2591709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Kwon Y, Kim HJ, Park S, Park Y-G, Cho K-H. Body mass index-related mortality in patients with type 2 diabetes and heterogeneity in obesity paradox studies: a dose-response meta-analysis. PloS One. 2017;12(1):e0168247. doi: 10.1371/journal.pone.0168247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Khalangot M, Tronko M, Kravchenko V, Kulchinska J, Hu G. Body mass index and the risk of total and cardiovascular mortality among patients with type 2 diabetes: a large prospective study in Ukraine. Heart. 2009;95(6):454–460. doi: 10.1136/hrt.2008.150524 [DOI] [PubMed] [Google Scholar]
  • 23.Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7(10):915–926. doi: 10.1016/S1474-4422(08)70193-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kawate N, Kayaba K, Hara M, Kotani K, Ishikawa S. Body mass index and stroke incidence in Japanese community residents: The Jichi Medical School (JMS) Cohort Study. J Epidemiol. 2017;27(7):325–330. doi: 10.1016/j.je.2016.08.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yoon K-H, Lee J-H, Kim J-W, Cho JH, Choi Y-H, Ko S-H, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–1688. doi: 10.1016/S0140-6736(06)69703-1 [DOI] [PubMed] [Google Scholar]
  • 26.Perry JR, Voight BF, Yengo L, Amin N, Dupuis J, Ganser M, et al. Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet. 2012;8(5):e1002741. doi: 10.1371/journal.pgen.1002741 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Tariq Jamal Siddiqi

27 Jul 2022

PONE-D-22-18934Body mass index and stroke risk among patients with diabetes mellitus in KoreaPLOS ONE

Dear Dr. Lee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 10 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Song et al. conducted a study on "Body mass index and stroke risk among patients with diabetes mellitus in Korea", in which they have demonstrated that there is a positive relation between BMI and and the risk of total stroke (hemorrhagic and ischemic), especially ischemic, among patients with diabetes mellitus in Korea. In my opinion, this study may be improved by incorporating the following points:

1. In the introduction, line 50 "Overweight or obesity are also established risk factors for developing cardiovascular diseases" has been repeated, please remove it.

2. Please provide a copy of the preliminary questionnaire if possible, used in the cohort in the accompanying supplement.

3. In the methods, please provide a reference if possible for the relevant guidelines and regulations the study was abided by, lines 89-90.

4. The study should mention more detail regarding the analysis technique. The study uses Cox proportional hazards model, more details are required as to why the Cox's model was used instead of any other type of effect size such as "Odds Ratios"

5. Was any software, website or any particular mathematical equation used to calculate the sample size ?

6. Presenting the p-values for the outcomes evaluated in the study in tables 2-5 may comprehensively highlight the significance of the results.

7. In the results section, only proportions (%) have been mentioned for the stroke incidence. Please mention the hazards ratio (HR) along with their p-values for stroke for the respective BMI classes in the results section as-well.

8. Please write the title of "Figure 1" above the figure itself and not at the start

9. Please proofread the manuscript for grammatical and typographical errors once again.

10. According to author, previous studies have been conducted evaluating the association between BMI and the risk of stroke in patients with DM but with contradictory findings. How does the present study distinguishes itself from the previously conducted studies, apart from a greater sample size ? Some more points on as to how the present results would meaningfully improve the accuracy and reliability compared with the predecessors would be better.

11. Please highlight the avenues for future research which have been opened up as a result of this study, or are needed to contextualize and further the findings presented in this study for better management, and prophylaxis of diabetic obese patients who are at a risk of stroke.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ahmed Kamal Siddiqi

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Sep 30;17(9):e0275393. doi: 10.1371/journal.pone.0275393.r002

Author response to Decision Letter 0


23 Aug 2022

PONE-D-22-18934

Body mass index and stroke risk among patients with diabetes mellitus in Korea

PLOS ONE

Dear Dr. Lee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 10 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf

and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

→Thank you for your kind comment. We revised the manuscript according to the PLOS ONE's style requirements.

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

→Thank you for your kind comment. All relevant data are within the paper. In addition, we presented the p-values for the outcomes in tables 2-5.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data?e.g. participant privacy or use of data from a third party?those must be specified.

Reviewer #1: Yes

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Song et al. conducted a study on "Body mass index and stroke risk among patients with diabetes mellitus in Korea", in which they have demonstrated that there is a positive relation between BMI and and the risk of total stroke (hemorrhagic and ischemic), especially ischemic, among patients with diabetes mellitus in Korea. In my opinion, this study may be improved by incorporating the following points:

1. In the introduction, line 50 "Overweight or obesity are also established risk factors for developing cardiovascular diseases" has been repeated, please remove it.

→ Thanks for your advice. As you suggested, we deleted that sentence.

2. Please provide a copy of the preliminary questionnaire if possible, used in the cohort in the accompanying supplement.

→ We attached the copy of the preliminary questionnaire of cohort database released by the Korean National Health Insurance Service.

3. In the methods, please provide a reference if possible for the relevant guidelines and regulations the study was abided by, lines 89-90.

→ Thank you for your kind comment. As you recommended, we provided the reference [16] about the relevant guidelines and regulations for strengthening the reporting of observational studies in epidemiology.

4. The study should mention more detail regarding the analysis technique. The study uses Cox proportional hazards model, more details are required as to why the Cox's model was used instead of any other type of effect size such as "Odds Ratios"

→ Thank you for your kind comment. Odds ratios are cumulative over an entire study, while hazard ratios represent instantaneous risk over the study time period. As you recommended, we changed the sentences “Incidence of stroke (ischemic or hemorrhagic) was the outcome of interest and was identified as ischemic stroke (ICD code I63) and hemorrhagic stroke (ICD codes I60-I62).” to “The outcome of interest was the time-to-stroke incidence. We defined stroke incidence as the first diagnosis of stroke. Stroke was identified as either ischemic stroke (ICD code I63) or hemorrhagic stroke (ICD codes I60-I62).”, line 102-104.

5. Was any software, website or any particular mathematical equation used to calculate the sample size?

→ We did not use any particular mathematical equation to calculate the sample size. Instead, we used all subjects who had received health checkup during the period were enrolled in the study.

6. Presenting the p-values for the outcomes evaluated in the study in tables 2-5 may comprehensively highlight the significance of the results.

→ Thank you for your kind comment. As you recommended, we presented the p-values for the outcomes in tables 2-5.

7. In the results section, only proportions (%) have been mentioned for the stroke incidence. Please mention the hazards ratio (HR) along with their p-values for stroke for the respective BMI classes in the results section as-well.

→ Thank you for your kind comment. As you recommended, we presented the hazards ratio (HR) along with their p-values for stroke for the respective BMI classes in the results section.

8. Please write the title of "Figure 1" above the figure itself and not at the start

→ When submitting the manuscript, figures are required to be submitted separately. As you recommended, we inserted the figure just below the title.

9. Please proofread the manuscript for grammatical and typographical errors once again.

→ Thank you for your kind comment. As you recommended, we proofreaded the manuscript for grammatical and typographical errors once again.

10. According to author, previous studies have been conducted evaluating the association between BMI and the risk of stroke in patients with DM but with contradictory findings. How does the present study distinguishes itself from the previously conducted studies, apart from a greater sample size ? Some more points on as to how the present results would meaningfully improve the accuracy and reliability compared with the predecessors would be better.

→ Thank you for your kind comment. As you recommended, “Levels of physical activity and family history of cardiovascular disease, which could influence the incidence of stroke were not adjusted in the aforementioned studies, and none of the participants were Korean [11, 12, 20, 22]. Subjects who had a medical history of illnesses that could cause low body weight—such as stroke, ischemic heart disease, cancer, or chronic obstructive pulmonary disease—were excluded from our study. However, subjects with chronic diseases such as cancer or chronic obstructive pulmonary disease were not excluded from the previous studies [11, 12, 20, 22].” were inserted in the discussion, line 193-199.

11. Please highlight the avenues for future research which have been opened up as a result of this study, or are needed to contextualize and further the findings presented in this study for better management, and prophylaxis of diabetic obese patients who are at a risk of stroke.

→ Thank you for your kind comment. “Randomized clinical trials will be necessary to evaluate the risk of stroke depending on changes in body weight or weight-loss therapies. More prospective studies are also needed to clarify the mechanism of the association between BMI and the risk of stroke in patients with DM.” were inserted in the discussion, line 257-260.

________________________________________

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ahmed Kamal Siddiqi

________________________________________

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

→ Thanks, we used PACE digital diagnostic tool.

Attachment

Submitted filename: Preliminary questionnaire_English.pdf

Decision Letter 1

Tariq Jamal Siddiqi

15 Sep 2022

Body mass index and stroke risk among patients with diabetes mellitus in Korea

PONE-D-22-18934R1

Dear Dr. Lee,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

Acceptance letter

Tariq Jamal Siddiqi

21 Sep 2022

PONE-D-22-18934R1

Body mass index and stroke risk among patients with diabetes mellitus in Korea

Dear Dr. Lee:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tariq Jamal Siddiqi

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Preliminary questionnaire_English.pdf

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES